Blood 2018 Jun 18

Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.

Related Questions

Would you offer rituximab maintenance for 2 years after a successful response to induction in a patient with splenic marginal zone lymphoma?

The answer will depend on age, performance status of the patient, thrombocytopenia, etc. No difference in OS was noted but freedom from progression was noted in rituximab group. 1 year did as good as 2 years maintenance.Kalpadakis et al., PMID 29914978